natgillin/translations-raw huggingface dataset:
The objective mentioned above is met with a process for producing a water, juice, and/or milk-based ready-to-drink jellified product comprising at least two separate homogeneous gel masses, wherein adjacent separate gel masses have different gel strengths, characterized in that it comprises the steps of, in order: 
HR P20120788 T1 PATENTNI ZAHTJEVI Postupak za proizvodnju instant želiranog proizvoda na bazi vode, soka i/ili mlijeka koji se sastoji od najmanje dvije razdvojene homogene mase gela, gdje susjedne razdvojene mase gela imaju različite čvrstoće gela, naznačen time što se sastoji u koracima, redom:
The following results were obtained: 
Dobiveni su sljedeći rezultati:
The process for preparing a vaccine composition as claimed in claim 14, wherein the conjugate obtained in b) is combined with diphtheria toxoid, tetanus toxoid, and acellular Bordetella pertussis antigens toxoid and filamentous hemagglutinin. 
Postupak za pripravu pripravka cjepiva prema zahtjevu 12 ili 13, naznačen time da se konjugat dobiven u koraku b) kombinira s toksoidom difterije, toksoidom tetanusa, 1 2 acelularna antigena Bordetella pertussis, koji su toksoid i filamentozni hemaglutinin.
A method according to claim 13, including the step of controlling the mechanisms while continuing to engage the motor after the draw mechanisms have been activated. 
Metoda u skladu sa patentnim zahtjevom 14, koja uključuje korak kontroliranja mehanizama (14) dok se nastavlja angažiranje motora (16) nakon što su mehanizmi za vuču aktivirani.
the X group contains a linear, cyclic or branched, saturated or unsaturated hydrocarbon chain, comprising 1 to 22 carbon atoms, optionally substituted, and optionally comprising heteroatoms, rings and/or heterocycles; 
gdje skupina X sadrži nerazgranati, prstenasti ili razgranati, zasićeni ili nezasićeni ugljikovodični lanac s 1 do 22 atoma ugljika, koji može biti supstituiran, te može sadržavati heteroatome, prstene i/ili heterocikle;
The dry powder formulation according to claim 1, wherein at least 90% of all said micronized particles of said active ingredients (c) have a volume diameter equal to or lower than 5.0 microns, and the volume median diameter of said particles is from 1.3 to 2.2 microns. 
Formulacija suhog praška prema patentnom zahtjevu 1, naznačeno time da se fine čestice a) miješaju u rasponu vremena između 2 i 15 minuta. Formulacija suhog praška prema patentnom zahtjevu 1 ili 2, naznačeno time da najmanje 90% mikroniziranih čestica aktivnih tvari ima volumni promjer jednak ili manji od 5,0 mikrona.
In contrast to HI chromatography, adsorption of antibodies from cell culture supernatants on HCIC resin is accomplished without the need of any pH or ionic strength adjustment. 
Nasuprot kromatografiji HI, adsorpcija protutijela iz supernatanata staničnih kultura sc na smolu HCIC postiže bez potrebe za podešavanjem pH ili ionske jakosti.
The modular data center of claim 7, wherein the cable tray is supported by a hanger, the hanger in turn being coupled to the frame structure. 
Modularni podatkovni centar prema zahtjevu 7, naznačen time što je nosač kabela oslonjen na vješalicu (34, 36), te je vješalica povezana na konstrukciju okvira (28).
said reaction is performed for a time period of no more than 1.5 h, such as no more than 1 h, such as no more than 0.75 h, such as around 0.5 h, and 
iii) spomenuta reakcija se izvodi tokom vremenskog peroida najduže do 1,5 sata, kao što je najduže do 1 sata, kao što je najduže do 0,75 sata, kao što je oko 0,5 sata, i
We have now surprisingly discovered that certain novel cis-isomeric derivatives of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine are useful as antidepressant agents. 
Mi smo sada neočekivano otkrili da su izvjesni cis-izomerni derivati 4-fenil-1,2,3,4-tetrahidro-1-naftalinamina, dobiveni postupkom iz sadašnjeg izuma, korisna antidepresivna sredstva.
The locking device according to claim 1, wherein the locking device is an integrated part of the module. 
Uređaj za zaključavanje (1) prema zahtjevu 1, naznačen time da je uređaj za zaključavanje (1) integralni dio sjedalice (3) ili njenog nosača. t>&
For example, this can occur such that above or below or between pieces of wood at least one material is arranged being different from wood. 
Na primjer, to se može dogoditi tako da se iznad ili ispod ili između komada od drva stavi najmanje jedan materijal koji je različit od drva.
the compound of formula IIBb/tenofovir disoproxil fumarate/GS-9131/elvitegravir, 
Farmaceutski sastav prema patentnom zahtjevu 7, koji sadrži kombinaciju spoja formule IIBb/tenofovir dizoproksil fumarat/atazanavir.
reaction of a compound of Formula (4) with a compound of Formula (5): wherein X is a leaving group; or 
reakciju spoja formule (4) sa spojem formule (5): [image] pri čemu X je odlazna skupina; ili
precipitating IgG from the suspension with between about 20% and about 30% alcohol at a pH of between about 6.7 and about 7.3 to form a second precipitate, 
taloženje IgG iz suspenzije s oko 20% do oko 30% alkohola i na pH-vrijednosti od oko 6,7 do oko 7,3, za tvorbu drugog taloga,
the first variant Fc-region polypeptide differs from the second variant Fc-region polypeptide in one or more amino acid residues other than those amino acid residues in which the first parent IgG class Fc-region polypeptide differs from the second parent IgG class Fc-region polypeptide, and 
polipeptid prve varijante Fc regije razlikuje od polipeptida druge varijante Fc regije u jednom ili više aminokiselinskih ostataka, osim aminokiselinskih ostataka u kojima se matični polipeptid prve varijante Fc regije klase IgG razlikuje od matičnog polipeptida druge varijante Fc regije klase IgG, i
The synthesis is carried out in a manually operated 1 L stirred batch reactor equipped with sintered glass frit under nitrogen. 
Sinteza se provela u ručno operiranom jedno-litarskom šaržnom reaktoru opremljenim sa sinteriranom staklenom fritom (smrvljena masa) pod atmosferom dušika.
and the stereoisomeric forms and racemic mixtures thereof, in which R1 is alkyl or arylalkyl and R2 is alkyl or arylalkyl, providing that when R2 is methyl R1 is not methyl or ethyl. 
(Va) injihovi stereoizomerni oblici i racematne smjese, pri čemu R! je alkil ili arilalkil i R- je alkil ili arilalkil, pod uvjetom da kada R? je metil R! je nije metil ili etil.
In a class of this embodiment, in step 5), after adding excess NH4Cl to the H2RuCl6 solution, the H2RuCl6 solution is stirred at 100-400 revolutions per minute for 1-3 hours. 
Postupak prema zahtjevu 1 ili 2, naznačen time što su u koraku 5) otopina H,RuCL miješa na 100-400 o/min tijekom 1-3 sata.
The invention also pertains to a kit for male contraception comprising means for the administration of a progestagen and means for the administration of an androgen, characterised in that one of the means is a pharmaceutical composition comprising a compound according to the present invention. 
Ovaj izum također se odnosi na komplet za mušku kontracepciju, koji sadrži sredstva za primjenu progestagena i sredstva za primjenu androgena, gdje je jedno od sredstava farmaceutski pripravak koji sadrži spoj prema ovom izumu.
A compound of any one of claims 1 to 10 for use in preventing, modulating or treating diabetes, hyperglycemia, impaired glucose tolerance, gestational diabetes, insulin resistance, hyperinsulinemia, retinopathy, neuropathy, nephropathy, diabetic kidney disease, acute kidney injury, cardiorenal syndrome, acute coronary syndrome, delayed wound healing, atherosclerosis and its sequelae, abnormal heart function, congestive heart failure, myocardial ischemia, stroke, Metabolic Syndrome, hypertension, obesity, fatty liver disease, dislipidemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low high-density lipoprotein, high low-density lipoprotein, non-cardiac ischemia, pancreatitis, lipid disorders, neurodegenerative disease, cognitive impairment, dementia, liver diseases and liver cirrhosis. 
Jedinjenja iz patentnih zahtjeva 1 do 10 za primjenu u prevenciji, modulaciji ili liječenju dijabetesa, hiperglikemije, narušene tolerancije glukoze, gestacionog dijabetesa, inzulinske rezistencije, hiperinzulinemije, retinopatije, neuropatije, nefropatije, dijabetske bolesti bubrega, akutne bubrežne povrede, kardiorenalnog sindroma, akutnog koronarnog sindroma, odloženog zarastanja rana, ateroskleroze 1 njenih posledica, abnormalne srčane funkcije, kongestivne srčane slabosti, ishemije miokarda, moždanog udara, metaboličkog sindroma, hipertenzije, gojaznosti, masne jetre, dislipidemije, hiperlipidemije, hipertrigliceridemije, hiperholesterolemije, niskih lipoproteina visoke gustine, visokih lipoproteina niske gustine, nekardijačne ishemije, pankreatitisa, lipidnih poremećaja, neurodegenerativnih bolesti, kognitivnog oštećenja, demencije, bolesti jetre i ciroze jetre.
The boom mountable robotic arm of claim 7 wherein said pivotal coupling includes a hinge. The boom mountable robotic arm of claim 8 wherein each said hinge includes at least one hinge plate, each said hinge plate having a plurality of bores therein for securing a corresponding said pair of electrically insulated support posts thereto. 
Robotska ruka koja se može montirati na istaknuti podupirač, prema zahtjevu 5, naznačena time, da svaki od navedenih zglobova, obuhvaća najmanje jednu zglobnu ploču, gdje svaka zglobna ploča ima na sebi veći broj provrta za osiguravanje odgovarajućeg para električno izoliranih potpornih stupova na tom mjestu.
and/or in the preparation of compound 5, the ratio of the volume of the solvent to the mole of compound 7 is in the range of 1.0-3.0 L/mol; 
i / ili u pripremi spoja 5, omjer volumena otapala prema molu spoja 7 je u rasponu 1,0-3,0 L/mol;
Use according to Claim 6, wherein said cancer is dependent upon Met activation, wherein said Met activation is regulated by gene amplification, an activated Met mutation and/or HGF stimulation. 
Uporaba prema zahtjevu 6, gdje je spomenuti rak ovisan o Met aktivaciji, pri čemu je ta Met aktivacija regulirana umnažanjem gena, aktiviranom Met mutacijom i/ili HGF stimulacijom.
Delivery of an iRNA of the Invention 
Datum podnošenja europske prijave patenta:
A pharmaceutical composition as in Embodiment 1, comprising 
Farmaceutski sastav prema zahtjevu 1, koji obuhvaća
Method of producing a cement comprising Portland cement clinker and a clinker replacement material comprising the steps of a) providing a carbonate material and a clay material, b) treating said carbonate material and said clay material, optionally in a mixture, in such a way that no chemical reaction occurs between the clay minerals and the carbonate material when subsequently mixed, c) mixing said carbonate material and said clay material, and d) blending the mixture of a carbonate material and a clay material with a Portland cement clinker. A method according to claim 11, wherein the clay material is heat-treated separately before mixing with the carbonate material. A method according to claim 11, wherein the carbonate material and the clay material are calcined in a mixture at a temperature of less than 800°C, and preferably less than 700 °C. 
Postupak za proizvodnju cementa koji sadrži Portland cementni klinker i dodatni cementni materijal koji sadrži korake a) pribavljanja karbonatnog materijala odabranog iz skupine koja sadrži vapnenac, magnezijev karbonat, kalcijev magnezijev karbonat, ili njihove smjese, navedeni karbonatni materijal se usitnjava do specifične površine od 3000 - 15000 cm2/g određeno Blainovim postupkom opisanim u EN 196 i glineni materijal, b) odvojeno zagrijavanje glinenog materijala na temperaturi od između 500ºC i 900ºC, c) miješanje toplinski obrađenog glinenog materijala s karbonatnim materijalom u masenom omjeru toplinski obrađenog glinenog materijala prema karbonatnom materijalu od između 0.25 i 3, i d) miješanje smjese iz c) s Portland cementnim klinkerom. Postupak prema zahtjevu 13 naznačen time što se toplinski obrađeni glineni materijal proizvodi u rotacijskoj peći ili peći sa fluidiziranim slojem.
The liquefied gas treatment system according to claim 7, further comprising BOG consuming means configured to receive and uses BOG that is compressed while passing through a part of the plurality of compression cylinders (14) included in the compressor (13). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 4, naznačen time što otpareni plin poslan u izmjenjivač topline (21) je otpareni plin komprimiran prilikom prolaska kroz sve ili dio kompresijskih elemenata koje sadrži kompresor (13,13,13b).
identifies a maximum in said similarity values as corresponding to a time of arrival of said reflected pulse of output ultrasonic vibrations. 
(ii) identificira maksimum u navedenim vrijednostima sličnosti kao odgovarajući vremenu dolaska navedenog trenutnog impulsa izlaza ultrazvučnih vibracija.
The diphenyl sulfide derivative according to claim 1, or a pharmaceutically acceptable salt or hydrate thereof, wherein the compound represented by the general formula (1) is represented by the general formula (1c), (In the formula (1c), R1 and R2 are as defined above). 
Derivat difenil-sulfida u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol ili hidrat, naznačen time što je spoj prikazan općom formulom (1) prikazan općom formulom (1c), [image], gdje su u formuli (1c) R1 i R2 definirani kao gore.
It commences on the already existing plate-shaped composite structure comprising a multiplicity of arrangements 1 and is firstly distinguished in that the groove structures 4 of the plate-shaped composite structure are produced so that they are continuously joined to each other in at least one direction via the lines 6, from one edge to the opposite edge of the plate-shaped composite structure. 
On započinje na već postojećoj pločastoj kompozitnoj strukturi koja obuhvaća više naprava 1 i najprije se odlikuje s tim brazdastim strukturama 4 pločaste kompozitne strukture koje su proizvedene tako da su one međusobno spojene bez prekida u najmanje jednom smjeru po linijama 6, od jednog do drugog, suprotnog ruba pločaste kompozitne strukture.
For column sanitization, the column was flushed in backflow with at least 3 BV of NaOH 0.5 M and then rinsed with 4-5 BV of purified water. 
Za sterilizaciju kolone, ista je bila oprana obrnutim protokom s najmanje 3 BV 0.5 M NaOH, a nakon toga je oprana s 4- 5 BV pročišćene vode.
amplifying the treated DNA by means of an oligonucleotide comprising or consisting of a sequence as defined by SEQ ID NO: 5, or variants thereof with 5'-terminal and/or 3'-terminal deletion of 1, 2, 3, 4 or 5 nucleotides, said one or more oligonucleotides are suitable for use as primers; and 
Uporaba oligonukleotida ili smjese oligonukleotida u postupku sukladno bilo kojem od patentnih zahtjeva 1-4, navedeni oligonukleotid ili oligonukleotidi navedene smjese sadrže ili se sastoje od sekvence odabrane iz skupine sastavljene od SEK ID BR: 6, 44-48, 62-64, 2, i 16-22 i njihove inačice s 5’-terminalnom i/ili 3’-terminalnom delecijom nukleotida 1, 2, 3, 4 ili 5.
Production Of Ani-C1ORF32 Monoclonal Antibodies Of The Invention 
Datum podnošenja europske prijave patenta:
A light source as claimed in claim 16, claim 17 or claim 18, wherein the sealed plug is recessed and a second plug is provided in the counter-bore flush with the crucible at outer surfaces thereof. 
Svjetlosni izvor u skladu s patentnim zahtjevom 16, patentnim zahtjevom 17 ili s patentnim zahtjevom 18, naznačen time, da je hermetički zatvoreni čep upušten, a u upustivom dijelu nalazi se drugi čep koji je poravnat s vanjskom površinom retorto.
said hormonal agent is selected from leuprorelin, goserelin, triptorelin, buserelin, tamoxifen, toremifene, flutamide, nilutamide, cyproterone bicalutamide anastrozole, exemestane, letrozole, fadrozole medroxy, chlormadinone, megestrol, other LHRH agonists, other anti-estrogens, other anti-androgens, other aromatase inhibitors, and other progestogens; 
Oblik prema zahtjevu 33 ili 34, gdje se taj hormon izabire između leuprorelina, goserelina, triptorelina, buserelina, tamoksifena, toremifena, flutamida, nilutamida, ciproterona, bikalutamida, anastrozola, eksemestana, letrozola, fadrozola, medroksi, klormadinona, megestrola, drugih LHRH agonista, drugih anti-estrogena, drugih anti-androgena, drugih inhibitora aromataze i drugih progestagena.
A method according to claim 3, wherein the high molecular weight PEO comprises at least about 80% (by weight) of each dosage form. 
Oblik doziranja s produljenim otpuštanjem prema zahtjevima od 1 do 11, naznačen time da sastojak sadrži barem oko 80 % (po težini) polietilen oksida.
The pyridylaminoacetic acid compound or pharmacologically acceptable salt thereof according to claim 1, wherein the pyridylaminoacetic acid compound is: 
Farmaceutski sastav koji sadrži spoj piridilaminooctene kiseline prema zahtjevu 1 ili 2 ili njegovu farmakološki prihvatljivu sol kao aktivni sastojak.
reacting Compound (D) or a pharmaceutically acceptable salt thereof with H2 in the presence of a Pd catalyst on carbon (Pd(0)/C) to form Compound (F) or a pharmaceutically acceptable salt thereof; 
(D reakciji Spoja (D), ili njegove farmaceutski prihvatljive soli, s H2, u prisutnosti Pd katalizatora na ugljiku (Pd(0)/C), kako bi se dobilo Spoj (F) O.
Use of prolactin receptor neutralizing antibodies or antigen-binding fragments thereof for the treatment and/or prevention of endometriosis and adenomyosis (endometriosis interna). 
Antitijelo ili fragment koji veže antigen prema bilo kojem od zahtjeva 1 do 4 naznačeno time da je za uporabu kao lijek za liječenje i/ili prevenciju endometrioze i adenomioze (endometriosis interna).
under suitable metal catalyzed cross-coupling conditions to form an adduct containing a protected amine group; and 
[image] pod pogodnim metalnim kataliziranim uvjetima umrežavanja, da se dobije adukt koji sadržava zaštićenu amino skupinu;
In yet another embodiment of the composition described herein, the composition is free of rasagiline base. 
Sastav prema patentnom zahtjevu 7, naznačen time, da jest bez rasagilinske baze.
31A) The construct for CLTA1 sgRNA expression (top) was designed to generate transcripts containing the original Cas9-binding sequence (v1.0), or dsRNA duplexes extended by 4 base pairs (v2.1) or 10 base pairs (v2.2). 
(1i) navedeni dsRNA dupleks ima duljinu od 8 parova baza (bp) do 30 bp; ili (ili) navedeni dsRNA dupleks ima duljinu od 15 parovi baza (bp) do 18 bp.
When sample loading was completed, the column was flushed with 7-9 BV of equilibration buffer. This fraction contains residual cell culture impurities. 
Nakon završetka nanošenja, kolona je oprana s 7-9 BV uravnotežujućeg pufera, Ova frakcija sadrži nečistoće iz stanične kulture.
The glycosylated human SAP polypeptide of any one of claims 1-3, wherein the oligosaccharide chain comprises at least one branch having the structure NeuNAc2a3GalB4GlcNAcB2Mana6. 
Glikozilirani humani SAP polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time, da oligosaharidni lanac sadržava najmanje jednu granu koja ima strukturu NeuNAc2a3Gal4GlcNAc2Mana6
In one embodiment, the invention provides an isolated fusion protein that exhibits at least about 80%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%, or 100% sequence identity to a sequence selected from Table 40, Table 41, Table 42, Table 43, and Table 44. 
Izolirani fuzijski protein prema jednom od zahtjeva 5 do 9, naznačen time, da biološki aktivan protem ima najmanje 95%, ili najmanje 96%, ili najmanje 97%, ili najmanje 98%, ili najmanje 99% ili 100% identiteta sekvence prema peptidu koji regulira glukozu, 1 odabran je iz skupine koja se sastoji od GLP-1 (SEQ ID NO: 20), GLP-2 (SEQ ID NO: 24), eksendin-4 (SEQ ID NO: 12), i glukagon (SEQ ID NO: 19).
The pharmaceutical composition according to claim 4 wherein the active agents are selected from steroids, hormones, proteins, trophic factors, vitamins, non-steroid anti-inflammatory drugs, chemotherapy drugs for topical use, antibiotics, antiviral agents, local anesthetics, anticoagulants and/or fibrinolytic agents, enzymes and/or other proteases. 
Farmaceutski pripravak za upotrebu prema prethodnim patentnim zahtjevima 3 ili 4, koji sadržava steroide, hormone, proteine, tropičke faktore, vitamine, nesteroidne protuupalne lijekove, lijekove za kemoterapiju za topikalnu primjenu, antibiotike, antivirusna sredstva, lokalne anestetike, antikoagulanse i/ili fibrinolitička sredstva, enzime i/ili druge proteaze.
In this study, the frequency of odor-related adverse events was noted to be higher on active drug (hydrochloride salt) versus placebo as summarized in the table below: 
U ovoj studiji, primijećeno je da je frekvencija štetnih događaja povezanih s mirisom viša kod lijeka s aktivnom tvari (hidrokloridna sol) u usporedbi s placebom, kao što je sažeto prikazano u tablici ispod:
The boom mountable robotic arm of claim 1 further comprising a base member mountable to a distal end of one of said at least one electrically insulated support post and a pivotable support plate pivotally mounted on said base member, said pivotable support plate adapted for mounting at least one electrical conductor retainer thereto. 
Robotska ruka koja se može montirati na krak dizalice prema zahtjevu 1, naznačena time, da nadalje obuhvaća temeljni element koji se može montirati na distalni kraj jednog od navedenih od barem jednog električno izoliranog podupirača, te stožernu nosivu pločicu koja je stožerno montirana na navedeni temeljni element, pri čemu je stožerna nosiva pločica namještena tako, da se na nju montira barem jedan električni osigurač vodiča.
The CD19xCD3 bispecific single chain antibody construct for the use of claim 1 or 2, wherein said acute lymphoblastic leukemia (ALL) is relapsed after allogenic hematopoietic stem cell transplantation and/or refractory to chemotherapy. 
CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što navedena akutna limfoblastična leukemija (ALL) ne reagira na kemoterapiju kod pacijenata neprikladnih za presađivanje alogenih krvotvornih matičnih stanica.
The method of claim 11, wherein the remaining amino acids are then coupled by a N-terminal synthetic strategy. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time, da su preostale aminokiseline potom povezuju strategijom sinteze N-terminala.
Meldonium phosphate (1:1). 
Meldonij fosfat(1:1)
is selected from hydrogen, CORa, COORa, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, and substituted or unsubstituted C4-C12 alkenynyl; is selected from substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; 
Ra se bira između vodika, COR,, COOR, supstituiranog ili nesupstituiranog C;-C,> alkila, supstituiranog ili nesupstituiranog C2-Cpx_ alkenila, supstituiranog ili nesupstituiranog C2-Ci2_ alkinila, 1 supstituiranog ili nesupstituiranog C4-C;2 alkeninila; Rio se bira između vodika, supstituiranog ili nesupstituiranog C;-C;> alkila, supstituiranog
a sensor element sensitive to a magnetic field generated by the magnetic element. 
senzorski element (22) osjetljiv na magnetsko polje koje generira magnetski element (21).
The cis -dihydrotetrabenazine compounds of the invention are typically administered in the form of pharmaceutical compositions. 
Cis-dihidrotetrabenazin spoj izuma se obično primjenjuje u obliku farmaceutskog pripravka.
The method according to claim 2, wherein the bacteriostatic agent is benzyl alcohol. 
Spremnik prema zahtjevu 9, naznačen time da bakteriostatsko sredstvo je benzil alkohol.